BACKGROUND: Hepatitis B virus (HBV) often persists after resolution, but its replication is suppressed by antiviral T cells. Immunosuppressive treatment may lead to viral reactivation and severe hepatitis. Early antiviral therapy prevents reactivation but some occult HBV infections are not easily detectable. RESULTS: Here we describe a patient with a progressive non-Hodgkin lymphoma who had probably not been vaccinated against HBV and, before immunosuppression, showed antibodies (anti-HBs) against the viral surface antigen (HBsAg) as the only possible marker of occult HBV infection. Under immunosuppression he developed viremia (>10(8)copies/mL). The virus exhibited three S gene mutations (L109R, C137W, G145R) which led to false negative HBsAg results and diminished binding of vaccine-induced anti-HBs. CONCLUSIONS: Reliable screening and monitoring of severely immunosuppressed patients for HBV should include, in addition to anti-HBc and HBsAg, anti-HBs and sensitive HBV DNA assays. Furthermore, active vaccination or hepatitis B immune globulin may not protect against such mutants.
BACKGROUND:Hepatitis B virus (HBV) often persists after resolution, but its replication is suppressed by antiviral T cells. Immunosuppressive treatment may lead to viral reactivation and severe hepatitis. Early antiviral therapy prevents reactivation but some occult HBV infections are not easily detectable. RESULTS: Here we describe a patient with a progressive non-Hodgkin lymphoma who had probably not been vaccinated against HBV and, before immunosuppression, showed antibodies (anti-HBs) against the viral surface antigen (HBsAg) as the only possible marker of occult HBV infection. Under immunosuppression he developed viremia (>10(8)copies/mL). The virus exhibited three S gene mutations (L109R, C137W, G145R) which led to false negative HBsAg results and diminished binding of vaccine-induced anti-HBs. CONCLUSIONS: Reliable screening and monitoring of severely immunosuppressed patients for HBV should include, in addition to anti-HBc and HBsAg, anti-HBs and sensitive HBV DNA assays. Furthermore, active vaccination or hepatitis B immune globulin may not protect against such mutants.
Authors: Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba Journal: Support Care Cancer Date: 2012-08-30 Impact factor: 3.603
Authors: Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel Journal: Wien Klin Wochenschr Date: 2010-05-04 Impact factor: 1.704
Authors: Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam Journal: World J Gastroenterol Date: 2016-07-28 Impact factor: 5.742
Authors: A Mühlbacher; B Weber; P Bürgisser; A Eiras; J Cabrera; S Louisirirotchanakul; F-W Tiller; H-S Kim; J v Helden; V Bossi; J-M Echevarria Journal: Med Microbiol Immunol Date: 2007-09-21 Impact factor: 3.402
Authors: Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller Journal: Clin Gastroenterol Hepatol Date: 2009-07-01 Impact factor: 11.382
Authors: Eleanor A Powell; Maemu P Gededzha; Michael Rentz; Nare J Rakgole; Selokela G Selabe; Tebogo A Seleise; M Jeffrey Mphahlele; Jason T Blackard Journal: J Med Virol Date: 2014-08-27 Impact factor: 2.327